Creative Medical reports pilot study of Ultrasome meets priamry endpoint

Creative Medical (CELZ) announced results from its pilot study of Ultrasome, the company’s cell-free regenerative therapy for the treatment of osteoarthritis of the knee. The study achieved its primary endpoint with 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse events reported. Ultrasome is derived from the company’s GMP-manufactured cell therapy product CELZ-201, which is currently being evaluated in the company’s FDA-cleared ADAPT clinical trial. The company said this relationship establishes a direct connection between CELZ’s clinical-stage biologic platform and its next-generation cell-free regenerative strategy, expanding the potential applications of CELZ-201 into broader, high-volume indications.